BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/3/2014 11:56:00 AM | Browse: 1042 | Download: 963
Publication Name World Journal of Clinical Oncology
Manuscript ID 1329
Country/Territory Netherlands
Received
2012-12-03 16:50
Peer-Review Started
2012-12-04 15:47
To Make the First Decision
2012-12-27 11:54
Return for Revision
2012-12-28 09:32
Revised
2013-01-10 00:17
Second Decision
2013-06-06 09:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-06-06 12:28
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-06-20 14:54
Publish the Manuscript Online
2013-07-06 12:57
ISSN 2218-4333 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Role of E3 ubiquitin ligases in lung cancer
Manuscript Source Invited Manuscript
All Author List Barbara C Snoek, Leonie HAM de Wilt, Gerrit Jansen and Godefridus J Peters
Funding Agency and Grant Number
Corresponding Author Godefridus J Peters, PhD, Department of Medical Oncology, VU University Medical Center, CCA 1.40, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. gj.peters@vumc.nl
Key Words E3 ubiquitin ligases; Lung cancer; Ubiquitin-proteasome system; Proteasome inhibitors; Bortezomib; Apoptosis; Gene regulation; DNA repair
Core Tip E3 ubiquitin ligases catalyze ubiquitination of proteins for degradation by the 26S proteasome. They are important for many biological processes including cell cycle regulation, proliferation and apoptosis. They are often overexpressed and deregulated in lung cancer, which contributes to cancer development. These processes underline their potential as anti-cancer targets. There is only one E3 ubiquitin ligase inhibitor in clinical trial. A better understanding of how E3 ubiquitin ligases regulate biological processes and of their exact role in carcinogenesis, will help to develop specific E3 ubiquitin ligase inhibitors to improve treatment strategies for cancer patients.
Publish Date 2013-07-06 12:57
Citation Snoek BC, de Wilt LHAM, Jansen G, Peters GJ. Role of E3 ubiquitin ligases in lung cancer. World J Clin Oncol 2013; 4(3): 58-69
URL http://www.wjgnet.com/2218-4333/full/v4/i3/58.htm
DOI http://dx.doi.org/10.5306/wjco.v4.i3.58
Full Article (PDF) WJCO-4-58.pdf
Manuscript File 1329-Review.doc
Answering Reviewers 1329-Answering reviewers.doc
Copyright License Agreement 1329-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 1329-Language certificate.pdf
Peer-review Report 1329-Peer review(s).pdf
Scientific Editor Work List 1329-Scientific editor work list.doc